Results 121 to 130 of about 773 (143)

Power Plant Burners for Bio-Dust Combustion [PDF]

, 2015
Johansen, Joakim Myung
core  

The Effects of Trunk Intervention on Gross Motor Function, Balance, and Spasticity in Cerebral Palsy: Systematic Review and Meta-Analysis. [PDF]

Medicina (Kaunas)
Lim MS, Yoo BC, Lim HW.
europepmc   +1 more source

UltraAIGenomics: Artificial Intelligence-Based Cardiovascular Disease Risk Assessment by Fusion of Ultrasound-Based Radiomics and Genomics Features for Preventive, Personalized and Precision Medicine: A Narrative Review. [PDF]

Rev Cardiovasc Med
Saba L, Maindarkar M, Johri AM, Mantella L, Laird JR, Khanna NN, Paraskevas KI, Ruzsa Z, Kalra MK, Fernandes JFE, Chaturvedi S, Nicolaides A, Rathore V, Singh N, Isenovic ER, Viswanathan V, Fouda MM, Suri JS.   +17 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development

Pharmaceutical Research, 2022
Physiologically based biopharmaceutics modeling (PBBM) emphasizes the integration of physicochemical properties of drug substance and formulation characteristics with system physiological parameters to predict the absorption and pharmacokinetics (PK) of a drug product.
Min
exaly   +3 more sources

Applications of PBPK/PBBM modeling in generic product development: An industry perspective

Journal of Drug Delivery Science and Technology, 2022
Sivacharan Kollipara, Tausif Ahmed
exaly   +2 more sources

Best Practices for Integration of Dissolution Data into Physiologically Based Biopharmaceutics Models (PBBM): A Biopharmaceutics Modeling Scientist Perspective

AAPS PharmSciTech, 2023
Dissolution is considered as a critical input into physiologically based biopharmaceutics models (PBBM) as it governs in vivo exposure. Despite many workshops, initiatives by academia, industry, and regulatory, wider practices are followed for dissolution data input into PBBM models.
Sivacharan Kollipara, Adithya Karthik Bhattiprolu, Rajkumar Boddu   +2 more
exaly   +3 more sources

Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions

Xenobiotica, 2023
Over the past few years, PBPK and PBBM modelling have proven their significance in drug development. PBPK modelling is traditionally used to predict drug-drug interactions, exposures in special populations whereas PBBM modelling is a part of PBPK modelling that is used for a range of biopharmaceutics applications.Because of these differences in ...
Rajkumar Boddu, Sivacharan Kollipara, Gautam Vijaywargi   +2 more
exaly   +3 more sources

Novel application of PBBM to justify impact of faster dissolution on safety and pharmacokinetics – a case study and utility in regulatory justifications

Xenobiotica, 2023
Physiologically based biopharmaceutics modelling (PBBM) was recognised as potential approach for biopharmaceutics applications. However, PBBM to justify safety is an unexplored area.In this manuscript, we elucidated PBBM application for safety justification.
Rajkumar Boddu, Sivacharan Kollipara, Adithya Karthik Bhattiprolu   +2 more
exaly   +3 more sources

Towards Virtual Bioequivalence Studies for Oral Dosage Forms Containing Poorly Water-Soluble Drugs: A Physiologically Based Biopharmaceutics Modeling (PBBM) Approach

Journal of Pharmaceutical Sciences, 2022
The objective of the present study was to develop a physiologically based biopharmaceutics (PBBM) approach to predict the bioequivalence of dosage forms containing poorly soluble drugs. Aripiprazole and enzalutamide were used as model drugs. Variations in the gastrointestinal (GI) physiological parameters of fasted humans were taken into consideration ...
Atsushi Kambayashi
exaly   +3 more sources

Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies

Journal of Pharmaceutical Sciences, 2021
For oral drug products, in vitro dissolution is the most used surrogate of in vivo dissolution and absorption. In the context of drug product quality, safe space is defined as the boundaries of in vitro dissolution, and relevant quality attributes, within which drug product variants are expected to be bioequivalent to each other.
Tycho Heimbach, Martin Mueller-Zsigmondy, Sivacharan Kollipara   +2 more
exaly   +3 more sources